Top

Reactions Weekly

Published in:

01-04-2023 | Herpes Virus | Case report

Infliximab

Various toxicities: 4 case reports

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Mazza S, et al. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Clinical and Translational Science 15 : 172-181, No. 1, Jan 2022. Available from: URL: http://doi.org/10.1111/cts.13131

Title: Infliximab
Various toxicities: 4 case reports
Publication date: 01-04-2023
Publisher: Springer International Publishing
Keywords: Herpes Virus
Shingles
Infliximab
Joint Pain
Ulcerative Colitis
Crohn's Disease
Chronic Inflammatory Bowel Disease
Vulgar Psoriasis
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-37654-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Infliximab

Various toxicities: 4 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Lidocaine

Ibuprofen/prednisolone-acetate/prednisone

Multiple drugs

Bevacizumab

Regorafenib

Azithromycin